Cenicriviroc mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Cenicriviroc mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Cenicriviroc mesylate can convert its Small molecule drug profile and CCR2 x CCR5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Cenicriviroc mesylate (query alias: Cenicriviroc mesylate) |
|---|---|
| Modality / target | Small molecule drug; CCR2 x CCR5; CCR2 antagonists, CCR5 antagonists |
| Highest global status | Phase 3 |
| Originator | Tobira Therapeutics, Inc. |
| Active developers | Takeda Pharmaceutical Co., Ltd., Tobira Therapeutics, Inc. |
The MCP disease footprint includes Obesity, Cholangitis, Sclerosing, Cognition Disorders. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04593940 | Phase 3 | Completed | 1971 | Number of Participants Who Had Recovered by Day 28 |
| NCT04488081 | Phase 2 | Active, not recruiting | 1500 | Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19. |
| NCT05630885 | Phase 2 | Completed | 110 | Change (Expressed as Ratio to Baseline) in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index (Most-inflamed) Vessel. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
Phase 2; n=110; evaluation: not stated. Reported fields: Change (Expressed as Ratio to Baseline) in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index (Most-inflamed) Vessel.(Median) = 0.93 Fold-change (Inter-Quartile Range, 0.87 - 1.02); Change (Expressed as Ratio to Baseline) in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index (Most-inflamed) Vessel.(Median) = 0.95 Fold-change (Inter-Quartile Range, 0.85 - 1.01); Change (Expressed as Ratio to Baseline) in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index (Most-inflamed) Vessel.(Median): Slope = 0.984(95% CI, 0.916 - 1.056), P-Value = 0.65; P-Value = 0.40; P-Value = 0.63; P-Value = 0.71
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Phase 3; n=1971; evaluation: not stated. Reported fields: All-cause 28-day mortality = 15.1 % ; All-cause 28-day mortality = 13.8 % ; All-cause 28-day mortality = 11.0 %
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Phase 3; n=1971; evaluation: not stated. Reported fields: Number of Participants Who Had Recovered by Day 28 = 287 Participants ; Number of Participants Who Had Recovered by Day 28 = 414 Participants ; Number of Participants Who Had Recovered by Day 28: Recovery Rate Ratio = 1.122(95% CI, 0.987 - 1.275), P-Value = 0.0793; Recovery Rate Ratio = 1.120(95% CI, .984 - 1.275), P-Value = 0.0864; Recovery Rate Ratio = 1.006(95% CI, 0.862 - 1.176), P-Value = 0.9354
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Cenicriviroc mesylate addresses Obesity, Cholangitis, Sclerosing, Cognition Disorders. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-08-03 | AbbVie, Amgen, and Takeda collaborate on the I-SPY clinical trial to investigate the efficacy of cenicriviroc, Otezla, and Firazyr in treating Covid-19. | Approved | Financial terms not disclosed |
| 2017-04-18 | Novartis expands development programs for NASH through clinical collaboration with Allergan | Phase 3 | Financial terms not disclosed |
| 2016-04-12 | Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc | Phase 2 | US$0.5M upfront; US$2.5M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
